



WEO

The voice of world
endoscopy

Molecular pathways in post-colonoscopy versus detected colorectal cancers: results from a nested case–control study

Beatriz Carvalho, PhD

The Netherlands Cancer Institute



Disclosures

No disclosures.



Introduction

- Colonoscopy with polypectomy is not perfect in the prevention of CRC


3.7% (95% CI 2.8-4.9%) of all patients diagnosed with CRC underwent colonoscopy within 5 years¹

- Postcolonoscopy CRC (PC-CRC)²:


Proximal location

Flat macroscopic appearance

Smaller in size



Introduction – CRC development



Introduction

Molecular profile of PCCRCs: what do we know?

Author / Publication	Population	PC-CRC vs Detected CRC	P-value
Sawhney et al. Gastroenterology 2006	51 PC-CRCs, 112 prevalent CRCs	MSI: 30.4% vs 10.3%	0.003
Arain et al. Am J Gastro 2009	63 PC-CRCs, 131 prevalent CRCs	CIMP: 57% vs 33%	0.004
Shaukat et al. Dig Dis Sci 2010	63 PC-CRCs, 131 prevalent CRCs	BRAF: 28% vs 19%	0.180
Shaukat et al. Dig Dis Sci 2012	63 PC-CRCs, 131 prevalent CRCs	KRAS: 13% vs 29%	0.030
Nishihara et al. NEJM 2013	62 PC-CRCs, 585 prevalent CRCs	MSI: 25.0% vs. 13.6% CIMP: 30.2% vs. 15.0% BRAF: 21.7% vs. 13.8%	ns
Richter et al. Dig Dis Sci 2014	42 PC-CRCs, 226 controls	MSI: 40.5% BRAF: 16.7% vs 10.2% KRAS: 28.6% vs 36.7% NRAS: 7.1% vs 4.0% PIK3CA: 16.7% vs 12.4%	0.280 0.380 0.410 0.460
Woo Lee et al. Gut and Liver 2016	25 PC-CRCs, 261 controls	MSI: 32% vs 8.4%	0.002



Introduction

Non-polypoid CRNs

- Often located in the proximal colon¹
- Easily overlooked
- Challenging to resect endoscopically
- Distinct molecular features:
 - More often 5q loss²
 - More often BRAF mutations³
 - Less often 17p & 18q loss²
 - Less often APC & KRAS mutations³



Aim

To investigate the molecular profile of PCCRCs, including both the CIN and MSI related mechanisms, in a large population-based cohort

Hypothesis: PCCRCs have a molecular profile that is different from DCRCs, presumably more similar to non-polypoid and/or sessile serrated precursor lesions



Study population

Population-based database 2001-2010

- National pathology database/national cancer registry
- Cross-linkage with hospital data



Exclusion of patients with:

- Hereditary CRC
- IBD
- Previous history of CRC




Identification of PCCRCs

Definition: CRCs diagnosed 6 to 60 months after a colonoscopy that was negative for CRC



Methods - Most likely etiologic factors



Methods- Molecular analysis

- Whole genome DNA copy numbers

Low-coverage whole genome sequencing – Illumina

- DNA mutations → 8 most common CRC genes

Truseq amplicon cancer panel – Illumina

- MSI status


Pentaplex Promega kit

- CIMP status

Multiplex MSP – CIMP panel - CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1 (Weisenberger et al Nat Genet 2006)



Results – Tumor selection




Results – baseline characteristics


Features	PCCRCs (n=122)	DCRCs (n=98)	P value*
Mean age (SD)	71.8 (9.1)	69.4 (11.4)	0.089
Male (%)	70 (57.4)	57 (58.2)	1.000
Current/previous smoking (%)	28 (23.0)	21 (21.9)	0.980
Proximal location (%)	77 (63.6)	31 (31.6)	<0.001
Flat appearance (%)	58 (47.9)	27 (27.8)	0.004
T1 carcinoma (%)	21 (17.6)	5 (5.1)	0.009
Poor differentiation (%)	32 (29.6)	12 (12.8)	0.006
Mucinous histology (%)	17 (13.9)	13 (13.3)	1.000
Diverticulosis (%)	58 (47.5)	20 (20.8)	<0.001
Mean tumour size (SD)	3.6 (1.8)	4.6 (1.9)	<0.001



Results - Etiology of PCCRCs analyzed




Results – Tumor selection and analysis




Results- PCCRCs show less copy number alterations

Molecular feature analysis

A) All PCCRCs vs DCRCs



B) Biological PCCRCs vs detected CRCs




Corrected for age and gender




Results- PCCRCs are commonly CIMP-high

- Unsupervised hierarchical clustering
- Included molecular features:
 - Difference in univariate analysis of all PCCRC or biological PCCRC analyses
 - All mutations with observed prevalence of $\geq 9\%$
- Ward.D algorithm



Results- Overview



Conclusions

- MSI, hypermethylation and CIN pathways play a role in the development of PCCRCs
- Key molecular features of PCCRCs:
Less often 13q gain and 18q loss
More often hypermethylated and MSI
- Similar molecular features in NP-CRNs and SSA/Ps → suggesting important contribution to PCCRCs



Discussion

- First comprehensive examination of the role of CIN- and MSI-associated mechanisms

Strengths

- Well characterized population-based collection of PCCRCs, nested case-control design
- Most likely etiologic factors identified

Limitations

- Retrospective
- Limited number of available tissue samples



Statement

The clinical and molecular features observed in PCCRCs support the hypothesis that SSLs and non-polypoid CRNs are contributors to the development of these cancers



Acknowledgements



Department of Pathology

Gerrit Meijer
Remond Fijneman
Linda Bosch
Rinus Voorham
Sara de Vries

Genomics Core Facility

Christian Rausch
Ron Kerkhoven
Arno Velds
Marja Nieuwland

Molecular Pathology

Petra Nederlof
Maartje Vogel



Department of Pathology

Manon van Engeland
Veerle Melotte
Heike Grabsch

Department of Statistics and methodology

Bjorn Winkens

Department of Gastroenterology

Ad Masclee
Silvia Sanduleanu
Eveline Rondagh
Chantal le Clercq
Roel Bogie

VU university medical center



Department of Pathology-Tumor Genome Analysis Core

Bauke Ylstra
Daoud Sie
Martijn Cordes
Paul Eijk
Dirk van Essen

Department of Gastroenterology

Chris Mulder
Jochim Terhaar
sive Droste
Frank Oort
Sietze van Turenhout
Ilhame Ben Larbi



Department of Gastroenterology

Evelien Dekker
Thomas de Wijkerslooth
Joep Ijspeert
Manon van der Vlugt



Department of Pathology

Marius Nap
Prapto Sastrowijoto



University of Leeds, Leeds, UK

Phil Quirke

Leeds General Infirmary, Leeds, UK

Bjørn Rembacken

Hospital Vitkovice, Ostrava, Czech Republic

Martin Kliment

Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan

Tomio Arai





WEO

World Endoscopy
Organization

